Broad Institute conducts layoffs as it preps for cuts in federal funding; Dyne’s financingnews2025-07-01T15:29:05+00:00July 1st, 2025|Endpoints News|
INmune Bio’s Alzheimer’s drug fails Phase 2; BridgeBio sells some ATTR-CM royaltiesnews2025-06-30T15:09:25+00:00June 30th, 2025|Endpoints News|
BioCryst sells Orladeyo business in Europe; UCB gets a Phase 3 win for Finteplanews2025-06-27T14:47:00+00:00June 27th, 2025|Endpoints News|
Edgewise details pivotal plans in Becker muscular dystrophy; Kymera’s $250M offeringnews2025-06-26T15:08:30+00:00June 26th, 2025|Endpoints News|
Arbutus regains rights to hepatitis B asset in China; Forte’s $75M offeringnews2025-06-25T15:04:34+00:00June 25th, 2025|Endpoints News|
ArriVent plots next steps for lung cancer drug; Neuron23’s $96.5M raisenews2025-06-24T14:57:43+00:00June 24th, 2025|Endpoints News|
Formation Bio’s up to €545M licensing deal with Sanofi; Otsuka, Harbour BioMed team upnews2025-06-23T15:15:50+00:00June 23rd, 2025|Endpoints News|
FDA OKs new label expansions for Dupixent and Incyte’s Monjuvinews2025-06-20T14:15:46+00:00June 20th, 2025|Endpoints News|
Bavarian Nordic’s PRV goes for $160M; Biomea to advance GLP-1 into trialsnews2025-06-18T14:06:08+00:00June 18th, 2025|Endpoints News|
Prothena moves forward with layoffs; Aldeyra resubmits dry eye drug to FDAnews2025-06-17T15:11:04+00:00June 17th, 2025|Endpoints News|
